What are the odds of having undiagnosed high cholesterol without regular blood tests?
Evidence quality 4.38/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 3/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 2.9
35% lifetime chance
Most people underestimate this.
range 1 in 4.0 to 1 in 2.0
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Most people assume they would notice if something were seriously wrong with their health. High cholesterol produces no pain, no shortness of breath, and no visible symptoms, yet it is frequently ranked low among personal health worries unless a doctor has specifically flagged it. When asked to estimate the likelihood of silently elevated lipids, most adults with no diagnosis assume they are fine. The intuition is that a young-to-middle-aged person in reasonable apparent health cannot have a cholesterol problem, and that regular doctors' visits would catch it anyway. Neither assumption is well supported by the data.
Rough estimate: ~5% chance of having undiagnosed high cholesterol at any given time
Source: editorial intuition, not polled
Actual
~3 in 100 US adults have undiagnosed clinically elevated LDL cholesterol at any given time (NHANES 2017-2020)
US adults age 20+
Show derivation
The native figure (approx. 3 in 100 US adults undiagnosed with elevated LDL at any moment) is a point-in-time cross-sectional prevalence, not a lifetime probability. To estimate the lifetime probability of ever having an undiagnosed period of high cholesterol, two independent estimates are combined. First, the Framingham Offspring Study found that over a 30-year window, roughly 4 in 10 participants developed high LDL (>=160 mg/dL), and adjusted 30-year risks exceeded 50% for any dyslipidemia. Second, NHANES trend data show that approximately 27-28% of US adults have not had their cholesterol checked within the past 5 years at any given time. A US adult with a normal lifespan (ages 18-77, approximately 59 years of adult life) who does not screen regularly will spend meaningful stretches without a current lipid panel. Combining the ~40% lifetime incidence of high LDL with the probability that any given high-cholesterol episode goes undetected for at least several years given typical US screening behavior produces a central estimate of approximately 35% lifetime probability of having a period of undiagnosed high cholesterol. The 95% uncertainty range of 25-50% reflects variability in screening adherence (which has improved but remains incomplete), the declining but still substantial prevalence of high total cholesterol (from 18.3% in 1999-2000 to 11.3% in 2021-2023 per NCHS Data Brief 515), and demographic variation: undiagnosed rates are substantially higher among uninsured adults (63.8%), young men (83.1% of 18-29-year-old males with elevated LDL are unaware and untreated), and Hispanic and non-Hispanic Black adults. The estimate is conservative in that it counts only clinically elevated cholesterol (total >=240 mg/dL or LDL >=160 mg/dL), not the borderline-high range where cumulative incidence is even larger.
Caveats: This entry covers the probability of having undiagnosed high cholesterol defined…
This entry covers the probability of having undiagnosed high cholesterol defined as total cholesterol >=240 mg/dL or LDL >=160 mg/dL, the clinical thresholds most commonly used in US guidelines and NHANES reporting. Borderline-high cholesterol (total 200-239 mg/dL or LDL 130-159 mg/dL) affects a substantially larger share of the population, and many adults in those ranges are also unaware of their status, but they are not captured in the native statistic. The lifetime estimate is the probability of ever having a period during which cholesterol was clinically elevated and no current test result documented that elevation. It is not the probability of dying from cholesterol-related disease. High cholesterol is one risk factor among many for cardiovascular disease, and its impact varies substantially with smoking status, blood pressure, diabetes, and physical activity. Statin therapy has improved treatment rates over the past two decades, and total cholesterol prevalence has fallen, but the awareness gap among young adults and underserved populations remains large. The USPSTF recommends screening for lipid disorders in adults at increased cardiovascular risk, but there is no universal annual cholesterol screening recommendation in the US, meaning detection gaps can persist for years between tests.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Silent hypertension
What are the odds of having undiagnosed high blood pressure without regular monitoring?
Silent diabetes
What are the odds of having undiagnosed type 2 diabetes or prediabetes without blood glucose monitoring?
Adventure sports
What are the odds of a serious injury from regular participation in surfing, mountain biking, or rock climbing?
Drug-resistant infection
What is the risk of developing a serious antibiotic-resistant infection?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
High cholesterol earns its reputation as a silent condition. Total cholesterol above 240 mg/dL produces no headaches, no fatigue, and no visible signs. According to NCHS Data Brief No. 515, 11.3% of US adults had high total cholesterol during the 2021-2023 NHANES cycles, a figure that declined steadily from 18.3% in 1999-2000 as statin use increased but has plateaued since 2013-2014. The silence creates a detection problem: a person cannot feel their LDL, and absent a blood test there is no mechanism for awareness. The result is a persistent gap that NHANES data can measure but that individuals rarely contemplate for themselves.
The scale of that gap is documented in careful detail. Virani et al. (2023, JAMA Cardiology), analyzing ten consecutive NHANES cycles from 1999 to 2020, found that 42.7% of adults with LDL between 160 and 189 mg/dL were both unaware of their condition and untreated. Among those with LDL at 190 mg/dL or above, the figure was 26.8%, roughly 1 in 4. Combining these groups yields approximately 3 in 100 US adults carrying clinically elevated LDL at any given time without knowing it. The burden falls unevenly: among adults aged 18-29 with elevated LDL, an estimated 83% are unaware and untreated. Among those without health insurance, the rate exceeds 63%. The common assumption that routine doctors’ visits reliably catch this problem does not survive contact with the data.
The lifetime picture is considerably larger than the point-in-time snapshot. The Framingham Offspring Study, following 4,701 participants over up to 30 years, found that roughly 4 in 10 developed high LDL (>=160 mg/dL) over that window, with more than 6 in 10 developing any borderline-high lipid abnormality. Given that approximately 27-28% of US adults have not had a lipid panel in the past five years at any given time, many who develop elevated cholesterol will spend at least several years in that state before detection. The lifetime probability of ever having an undiagnosed period of high cholesterol — cholesterol above the clinical threshold with no current test documenting it — is estimated here at approximately 35% for the average US adult, with a plausible range of 25-50% depending on screening behavior and risk profile. That makes silent high cholesterol one of the more common undetected health conditions in the country, not a rare edge case confined to the medically disconnected.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] National Center for Health Statistics (CDC) — Total and High-density Lipoprotein Cholesterol in Adults: United States, August 2021-August 2023
Total and High-density Lipoprotein Cholesterol in Adults: United States, August 2021-August 2023- Statistic
11.3% of US adults age 20+ had high total cholesterol (>=240 mg/dL) during August 2021-August 2023- Excerpt
“"During August 2021-August 2023, 11.3% of adults age 20 and older had high total cholesterol." ”
- Source data from
- 2024-11-01
- Accessed
- 2026-05-03 · archived copy
- Calculation
- NCHS Data Brief No. 515 reports prevalence of high total cholesterol (>=240 mg/dL) in US adults from NHANES cycles covering August 2021 through August 2023. The overall prevalence was 11.3% (age-adjusted: 11.2%), highest in the 40-59 age group (16.7%) and similar between men (10.6%) and women (11.9%). This is the denominator anchor: roughly 11 in 100 US adults have total cholesterol at or above the clinical threshold at any given moment. Combined with estimates from Virani et al. (2023) that approximately 27-43% of those with clinically elevated LDL are unaware and untreated, this yields the native numerator of approximately 3 in 100 adults undiagnosed at any given time. Historical context: prevalence declined from 18.3% in 1999-2000 to 11.0% in 2013-2014 and has not changed significantly since, suggesting a floor below which current interventions are not pushing prevalence further.
-
[2] JAMA Cardiology — Virani et al. — Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020
Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020- Statistic
42.7% of US adults with LDL 160-189 mg/dL and 26.8% with LDL >=190 mg/dL were unaware and untreated in 2017-2020- Excerpt
“"Among those with an LDL-C of 190 mg/dL or greater, 1 in 4 are unaware and untreated, with higher proportions unaware and untreated in the 160 to 189 mg/dL range." ”
- Source data from
- 2023-11-01
- Accessed
- 2026-05-03 · archived copy
- Calculation
- Virani et al. analyzed 10 consecutive NHANES cycles (1999-2000 through 2017-2020), including 23,667 participants age 20 and older. In the most recent cycle (2017-2020), 6.1% of US adults had LDL 160-189 mg/dL and 2.1% had LDL >=190 mg/dL. Of the 6.1% with LDL 160-189 mg/dL, 42.7% (95% CI, 33.6%-52.3%; representing 6.1 million adults) were both unaware and untreated. Of the 2.1% with LDL >=190 mg/dL, 26.8% (representing 1.4 million adults) were unaware and untreated. Combined, approximately 3.2% of all US adults have clinically elevated LDL and are undiagnosed and untreated at any given time, consistent with the native numerator of 3 in 100. Demographic disparities are large: undiagnosed rates among 18-29-year-olds with elevated LDL were 83.1%; among uninsured adults, 63.8%; among Hispanic adults, 61.6%. The Framingham Offspring Study (Lloyd-Jones et al., 2007) separately estimated 30-year risk of developing high LDL at approximately 40%, which, combined with typical US screening gaps (~28% unscreened in any 5-year window), supports the normalized lifetime estimate of 35%.
-
[3] The American Journal of Medicine — Lloyd-Jones et al. — Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study
Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study- Statistic
30-year risk of developing high LDL (>=160 mg/dL) was approximately 40%; borderline-high LDL (>=130 mg/dL) risk exceeded 60% over 30 years- Excerpt
“"Over a 30-year period, approximately 6 of 10 participants developed borderline-high LDL cholesterol, and 4 of 10 developed high LDL cholesterol." ”
- Source data from
- 2007-07-01
- Accessed
- 2026-05-03 · archived copy
- Calculation
- Lloyd-Jones et al. estimated 10- to 30-year risks of developing dyslipidemia in 4,701 Framingham Offspring Study participants across age groups 30-34, 40-44, and 50-54. The 30-year risk of developing high LDL (>=160 mg/dL) was approximately 40% across age groups, with borderline-high LDL (>=130 mg/dL) exceeding 60%. When adjusted for baseline prevalence, cumulative lifetime risks were higher still. This study provides the foundation for estimating lifetime incidence of high cholesterol, showing that the cross-sectional prevalence of ~11% at any moment substantially understates the proportion of adults who will ever experience elevated cholesterol during their lives. Used in normalized.assumptions to bridge from point-in-time prevalence to lifetime probability: with ~40% of adults eventually developing high LDL, and ~28% unscreened at any given time, a substantial fraction will have at least one undiagnosed episode.